RenovoRx Inc (RNXT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.19-9.16%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · RNXT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 96.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
RNXT — earnings miss
Dated 2026-11-05
Results of Operations and Financial Condition. On November 5, 2026, RenovoRx, Inc. issued a press release announcing its financial results as of and for the quarter ended September 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Why it matters: More active centers can drive device use and sales. Falling short would weaken the expansion story.
Watch forThe company reports 36 or more active cancer centers by December 31, 2026. These centers must treat patients for profit.
Also watch forThe company reports fewer than 36 active centers at year-end, or fewer than 21 at the next update.
Why it matters: The trial's main test is whether the treatment helps patients live longer. A delay would push back this key clinical test.
Watch forThe trial reaches 86 events and completes in the first half of 2027, with topline data in the second half of 2027.
Also watch forThe trial does not complete by June 30, 2027, or the company moves the topline readout beyond 2027.
Why it matters: The company reported $9.5 million in cash and said it can fund operations into H2 2027. A shorter runway may raise funding pressure.
Worry ifA company update reports cash of at least $9.5 million and keeps the stated runway through H2 2027.
Less concerning ifThe company reports cash below $9.5 million and says its cash will run out before H2 2027. Or it announces new share financing.
Why it matters: Management said Q3 revenue would top Q2. A miss would break the run of record quarters.
Watch forQ3 2026 revenue is above $909,000, the Q2 level, and the company keeps its $3.75M-$4.25M full-year guide.
Also watch forQ3 revenue is $909,000 or less, or the company cuts its full-year guide below $3.75M.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$296 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $775 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,556 loss on $10,000 · 55.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.